FDA Brief

Warning letters Biologics

FDA warning letter to

NexCell Scientific Inc

High riskIssued Sep 11Posted Sep 22Center for Biologics Evaluation and Research

NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.

What happened

FDA inspected NexCell Scientific's facility from December 9–12, 2025, and February 3–5, 2026, and documented manufacture of an umbilical cord blood-derived total nucleated cell product for allogeneic use. FDA also reviewed the company website and a referenced white paper, which stated the product was intended to treat diseases and conditions such as inflammation, injuries, neurological conditions, and liver cirrhosis. The inspections found CGMP violations, including unvalidated manufacturing and aseptic processes, sterility test failures from August 2023 to June 2025 without root-cause investigations, inadequate environmental monitoring, and no independent quality unit.

What FDA found

  1. The product is an unapproved new drug because it is sold without an FDA-approved drug application.

    Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The product is an unlicensed biological product because it is marketed without an approved biologics license application (BLA).

    Section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1)
  3. The company has not validated its manufacturing process to show the product has the identity, strength, quality, and purity it claims.

    21 CFR 211.100(a)
  4. The company has not validated the aseptic process even though the product is represented as sterile.

    21 CFR 211.113(b)
  5. The company's finished-product testing is inadequate because it is limited to sterility testing, visual inspection, and one other test, without scientifically sound specifications and test procedures.

    21 CFR 211.160(b)
  6. The company did not investigate lots that failed sterility testing between August 2023 and June 2025 to find the root cause or determine impact on other lots.

    21 CFR 211.192

What FDA wants

Submit a written response within 15 working days outlining specific steps and documentation to address the violations and prevent recurrence. The response must also address continued distribution, remaining inventory, previously distributed lots, and the lack of an Investigational New Drug (IND) or approved BLA.

Who should pay attention

  • clinics and providers offering regenerative medicine injections
  • patients considering umbilical cord blood cell treatments
  • companies marketing or distributing allogeneic cell products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk